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ABSTRACT 
A new series of 2-[4-(azetidin-2-one)-3-Chloro-4-phenyl]-1H-Phenylbenzimidazoles  and 2-(thiazolidin-4-one)-Phenyl]-
1H-Phenylbenzimidazoles were synthesized by the reaction of schiff base [2-(4-aminophenyl)-Benzimidazole and 
substituted Benzaldehyde] with chloroacetyl chloride and mercaptoacetic acid respectively. The chemical structures of the 
synthesized compounds were confirmed by IR,
 1H-NMR, mass spectral and C, H, N analysis. The synthesized compounds 
were screened for antibacterial (Bacillus cereus, Escherichia coli, Micrococcus  luteus,  Klebssiela pneumoniae, 
Staphylococcus aureus and  Salmonella epidermidis),  antifungal (Aspergillus niger and Candida albicans), analgesic 
activity by writhing reflex method and anti-inflammatory activity by carrageenan induced paw edema method. The 
synthesized compound showed significant activity of antibacterial, antifungal, analgesic and anti-inflammatory activity 
comparable to that of standard. 
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INTRODUCTION 
Azetidinone and Thiazolidinone derivatives were reported to 
possess antibacterial, antifungal 
[1-2],
  antituberculor activity
 
[3], anti-HIV 
[4], analgesic, anti inflammatory 
[5] and 
ulcerogenic activity. 
[6] Benzimidazole derivatives were 
reported to possess antibacterial 
[7], antifungal 
[8], anti-
inflammatory
 [8], antiviral 
[9], antitumor 
[9], antioxidant
 [10] and 
  antihelmintic 
[11] activities. Therefore it was envisaged that 
compounds containing both the chemical moieties would 
result in compounds of interesting biological activities. In 
this present study 2-(4-aminophenyl)-benzimidazole 
[12] were 
treated with different substituted aromatic aldehydes to 
produce Schiff base. 
[13-14] The Schiff bases were subjected to 
addition reactions with chloroacetyl chloride in the presence  
 
*Corresponding author: Dr. N. Anbalagan, 
Pydah College of Pharmacy, 2-360, Patavala, Kakinada-
533127, Andhra Pradesh, India; Tel: +91-0884-2315344 
Fax: 0884-2315345; E-mail: anbupharm@yahoo.com 
of triethylamine and thioglycollic acid in the presence of 1, 
4dioxane-anhydrous zinc chloride to produce 2-azetidinone 
derivatives
 and 4-thiazolidinone derivatives respectively 
[15-16]  
was prepared as per Fig. 1.  The chemical structures of the 
synthesized compounds were confirmed by IR,
 1 H-NMR, 
mass spectral and elemental analysis. The synthesized 
compounds were screened for antibacterial (Bacillus cereus, 
Escherichia coli, Micrococcus  luteus, Klebssiela 
pneumoniae, Staphylococcus aureus and  Salmonella 
epidermidis),  antifungal (Aspergillus niger and Candida 
albicans), analgesic activity by writhing reflex method and 
anti-inflammatory activity by carrageenen induced paw 
edema method. 
 
MATERIAL METHODS 
CHEMISTRY 
The melting points were taken in open capillary tube and are 
uncorrected. The IR spectra of the compounds were recorded 
on ABB Bomem FTIR spectrometer MB104 with KBr Anbalagan et al. / Synthesis and Biological Activity of 2-(Thiazolidin-4-One) Phenyl]-………………. 
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pellets. 
1H-NMR spectra were recorded on 400 MHz-Joel 
GSX 400 using CDCl3 as solvent. The chemical shifts are 
reported as parts per million downfield from tetra methyl 
silane (Me4Si). Mass spectra were recorded on Shimadzu 
GC-MS QP 5000. Microanalyses for C, H and N were 
performed in Heraeus CHN Rapid Analyzer and analyses 
indicated by the symbols of the elements are within ± 0.4 % 
of the theoretical values. 
1H-NMR and IR spectra were 
consistent with the assigned structures. The purity of the 
compounds was checked by TLC on pre-coated aluminum 
sheets (Silica gel 60 F254 Merck-Germany) using (2:4) ethyl 
acetate: hexane and (3:4) petroleum ether (40-60°C): ethyl 
acetate as mobile phase and visualized by iodine vapors.  
General Method for the Synthesis of Schiff base (Ia-h) 
A mixture of 2-(4-aminophenyl) Benzimidazole (0.01 mol), 
substituted Benzaldehyde (0.01 mol) and a drop of acetic 
acid was dissolved in ethanol (25 ml) and heated on a steam 
bath for 45-60 min. The reaction mixture was allowed to 
stand at room temperature for 24 h, The product separated 
out was filtered, dried under vacuum and recrystallized by 
using warm ethanol.  The synthetic scheme of the title 
compounds are outlined in Scheme 1. 
Synthesis of 2-[4-(azetidin-2-one) 3-Chloro-4-phenyl]-1H-
Phenylbenzimidazole (A1-8) 
Chloroacetyl chloride (0.01mol) was added drop wise to a 
mixture of schiff base (0.01mol) and triethylamine (0.02 mol) 
in dioxane (25 ml) at room temperature. The mixture was 
stirred for 8 h and allowed to stand at room temperature for 3 
days. The contents were poured on crushed ice and the 
precipitate obtained was filtered, washed with 10 % w/v 
sodium bicarbonate solution, vacuum dried and recrystallised 
using absolute ethanol.  
Spectral data of synthesized compounds 
Compound A1: Yield = 48%, mp 250-252 ºC, Rf = 0.54, 
1H-
NMR (CDCl3) δ: 7.95 (m, 4H; BZ), 7.73 (m, 4H; Ph), 7.30-
7.46 (m, 5H; Ph), 4.49 (s, 1H; 4-CH), 3.57 (s, 1H; 3-CH). IR 
(KBr) cm
-1: 3506, 3384, 3048, 1694, 1269, 1176, 865, 808, 
731, 562, 541. EI-MS m/z: 373.74 (Calcd for C22H16N3ClO: 
373.82) Anal. Calcd for C22H16N3ClO: C, 61.05; H, 3.52; N, 
8.90. Found: C, 61.12; H, 3.32; N, 8.78.  
Compound A2: Yield = 44%, mp 230-232 ºC, Rf = 0.58, 
1H-
NMR (CDCl3) δ: 7.94 (m, 4H; BZ), 7.73 (m, 4H; Ph), 7.29-
7.57 (dd, 4H;Ph), 4.49 (s, 1H; 4-CH), 3.06 (s, 1H; 3-CH). IR 
(KBr) cm
-1: 3507, 3379, 3048, 1694, 1269, 1177, 865, 809, 
775, 731, 562, 506. EI-MS m/z: 408.18 (Calcd for 
C22H15N3Cl2O: 408.26) Anal. Calcd for: C, 55.03; H, 2.89; N, 
8.02. Found: C, 55.16; H, 2.99; N, 8.10.  
Compound A3: Yield = 38%, mp 258-260 ºC, Rf = 0.54, 
1H-
NMR (CDCl3) δ: 7.95 (m, 4H; BZ), 7.73 (m, 4H; Ph), 7.07-
7.45 (m, 4H; Ph), 4.49 (s, 1H; 4-CH), 3.57 (s, 1H; 3-CH). IR 
(KBr) cm
-1: 3507, 3064, 1696, 1267, 1116, 876, 758, 749, 
724, 575, 507. EI-MS m/z: 389.76 (Calcd for C22H16N3ClO2: 
389.82). Anal. Calcd for: C, 55.03; H, 2.89; N, 8.02. Found: 
C, 55.16; H, 2.98; N, 8.09.  
Compound A4: Yield = 54%, mp 248-250 ºC, Rf = 0.71, 
1H-
NMR (CDCl3) δ: 7.92 (m, 4H; BZ), 7.74 (m, 4H; Ph), 7.30-
7.46 (m, 4H; Ph), 4.48 (s, 1H; 4-CH), 3.61 (s, 1H; 3-CH), 
1.61 (s, 3H; CH3). IR (KBr) cm
-1: 3507, 3380, 3048, 1694, 
1269, 1176, 865, 808, 776, 562, 541. EI-MS m/z: 387.72 
(Calcd for C23H18N3ClO: 387.85). Anal. Calcd for: C, 53.41; 
H, 2.80; N, 11.70. Found: C, 53.52; H, 3.01; N, 11.92.  
Compound A5: Yield = 16%, mp 274-276 ºC, Rf = 0.80, 
1H-
NMR (CDCl3) δ: 7.95 (m, 4H; BZ), 7.73 (m, 4H; Ph), 7.30-
7.45 (m, 4H; Ph), 4.49 (s, 1H; 4-CH), 3.57 (s, 1H; 3-CH), 
2.98 (s, 3H; 4-N-CH3), 2.79 (s, 3H; 4-N-CH3). IR (KBr) cm
-
1: 3507, 3375, 3047, 1695, 1269, 1176, 865, 808, 776, 562, 
541. EI-MS m/z: 416.78 (Calcd for C24H21N4ClO: 416.89). 
Anal. Calcd for: C, 53.41; H, 2.80; N, 11.70. Found: C, 
53.56; H, 2.71; N, 11.88.  
Compound A6: Yield = 61%, mp 220 ºC, Rf = 0.56, 
1H-
NMR (CDCl3) δ: 7.97 (m, 4H; BZ), 7.72 (m, 4H; Ph), 7.27-
7.45 (m, 4H; Ph), 4.10 (s, 1H; 4-CH), 3.89 (s, 1H; 3-CH), 
2.18 (s, 3H; 4-OCH3). IR (KBr) cm
-1: 3468, 3067, 1689, 833, 
754, 702, 614. EI-MS m/z: 403.76 (Calcd for C23H18N3ClO2: 
403.85).  Anal. Calcd for   : C, 53.41; H, 2.80; N, 11.70. 
Found: C, 53.54; H, 2.66; N, 11.82.  
Compound A7: Yield = 46%, mp 238-240 ºC, Rf = 0.88, 
1H-
NMR (CDCl3) δ: 7.94 (m, 4H; BZ), 7.72 (m, 4H; Ph), 7.30-
7.45 (m, 3H; Ph), 4.49 (s, 1H; 4-CH), 3.57 (s, 1H; 3-CH), 
2.09 (s, 3H; 4-OCH3), 1.84 (s, 3H; 3-OCH3). IR (KBr) cm
-1: 
3507, 3382, 1694, 1269, 1176, 865, 808, 776, 562. EI-MS 
m/z: 434.76 (Calcd for C24H20N3ClO3: 434.88). Anal. Calcd 
for: C, 62.10; H, 3.98; N, 8.52. Found: C, 62.24; H, 3.81; N, 
8.39.  
Compound A8: Yield = 10%, mp 230-232 ºC, Rf = 0.72, 
1H-
NMR (CDCl3) δ: 7.95 (m, 4H; BZ), 7.73 (m, 4H; Ph), 7.23-
7.45 (m, 2H; Ph), 4.49 (s, 1H; 4-CH), 3.90 (s, 1H; 3-CH), 
2.28 (s, 3H; 3-OCH3), 2.09 (s, 3H; 4-OCH3), 1.82 (s, 3H; 5-
OCH3). IR (KBr) cm
-1: 3507, 3385, 3047, 1695, 1269, 1177, 
865, 809, 776, 526. EI-MS m/z: 465.78 (Calcd for 
C25H22N3ClO4: 465.92). Anal. Calcd for: C, 60.41; H, 4.51; 
N, 11.74. Found: C, 60.58; H, 4.38; N, 11.62.  
Synthesis of 2-[2-(thiazolidin-4-one) Phenyl]-1H-
Phenylbenzimidazoles (T1-8) 
To a mixture of schiff base (0.01 mol) and mercaptoacetic 
acid (0.01 mol) dissolved in dioxane (20 ml), anhydrous zinc 
chloride (0.004 mol) was added and refluxed for 8 h. The 
reaction mixture was cooled, filtered, washed with 10 % w/v 
sodium bicarbonate solution, vacuum dried and recrystallised 
using absolute ethanol. 
Compound T1: Yield = 64%, mp 208-210 ºC, Rf = 0.57, 
1H-
NMR (CDCl3) δ: 8.02 (m, 4H; BZ), 7.65 (m, 4H; Ph), 6.90-
7.44 (m, 5H; Ph), 4.15 (d, J = 2.1 Hz, 1H; 2-CH), 2.49 (s, 
2H; 5-CH2). IR (KBr) cm
-1: 3183, 1696, 1269, 1116, 783, 
757, 748, 638. EI-MS m/z: 371.32 (Calcd for C22H17N3OS: 
371.44). Anal. Calcd for: C, 71.13; H, 4.63; N, 11.32. Found: 
C, 71.12; H, 4.59; N, 11.28.  
Compound T2: Yield = 55%, mp 198-200 ºC, Rf = 0.62, 
1H-
NMR (CDCl3) δ: 8.01 (m, 4H; BZ), 7.64 (m, 4H; Ph), 6.90-
7.45 (dd, J = 2.1 Hz, 4H; Ph), 4.15 (d, J = 2.2 Hz, 1H; 2-CH), 
2.47 (s, 2H; 5-CH2). IR (KBr) cm
-1: 3182, 1693, 1228, 748, 
751, 723, 641, 503. EI-MS m/z: 405.78 (Calcd for 
C22H16N3ClOS: 405.89). Anal. Calcd for: C, 65.08; H, 3.97; 
N, 10.35. Found: C, 64.98; H, 3.93; N, 10.28.  
Compound T3: Yield = 87%, mp 258-260 ºC, Rf = 0.88, 
1H-
NMR (CDCl3) δ: 8.01 (m, 4H; BZ), 7.62 (m, 4H;  Ph), 6.98-
7.45 (m, 4H; Ph), 4.15 (d, J = 2.1 Hz, 1H; 2-CH), 2.49 (s, 
2H; 5-CH2). IR (KBr) cm
-1: 3185, 1704, 1228, 784, 747, 721, 
640, 504. EI-MS m/z: 387.26 (Calcd for: 387.45). Anal. 
Calcd for C22H17N3O2S: C, 68.92; H, 4.42; N, 10.85. Found: 
C, 69.08; H, 4.38; N, 10.83.  
Compound T4: Yield = 98%, mp 278-280 ºC, Rf = 0.57, 
1H-
NMR (CDCl3) δ: 8.09 (m, 4H; BZ), 7.63 (m, 4H; Ph), 6.97-
7.46 (m, 4H; Ph), 4.14 (d, J = 2.1 Hz, 1H; 2-CH), 2.36 (s, 
2H; 5-CH2), 1.59 (s, 3H; CH3). IR (KBr) cm
-1: 3186, 1712, 
1229, 1115, 783, 747, 723, 639. EI-MS m/z: 385.36 (Calcd Anbalagan et al. / Synthesis and Biological Activity of 2-(Thiazolidin-4-One) Phenyl]-………………. 
 
IJPSDR April-June, 2010, Vol 2, Issue 2 (115-119)  117
for: 385.45). Anal. Calcd for C23H19N3OS: C, 71.66; H, 4.97; 
N, 10.90. Found: C, 71.61; H, 4.85; N, 10.90.  
Compound T5: Yield = 84%, mp 208-210 ºC, Rf = 0.55, 
1H-
NMR (CDCl3) δ: 8.22 (m, 4H; BZ), 7.85 (m, 4H;  Ph), 6.96-
7.69 (m, 4H; Ph), 4.19 (d, J = 2.1 Hz, 1H; 2-CH), 2.51 (s, 
2H; 5-CH2), 2.16 (s, 3H; NCH3), 1.85 (s, 3H; NCH3). IR 
(KBr) cm
-1: 3137, 1711, 1229, 1113, 784, 745, 720, 638. EI-
MS  m/z: 414.36 (Calcd for C24H22N4OS: 414.52). Anal. 
Calcd for: C, 69.54; H, 5.35; N, 13.52.  Found: C, 69.50; H, 
5.29; N, 13.50.  
Compound T6: Yield = 84%, mp 258-260 ºC, Rf = 0.6, 
1H-
NMR (CDCl3) δ: 8.01(m, 4H; BZ), 7.65 (m, 4H; Ph), 6.90-
7.44 (m, 4H; Ph), 4.15 (d, J = 2.1 Hz, 1H; 2-CH), 2.49 (s, 
2H; 5-CH2), 2.28 (s, 3H; OCH3). IR (KBr) cm
-1: 3183, 1721, 
1229, 1111, 784, 743, 722, 640. EI-MS m/z: 401.38 (Calcd 
for: 401.47). Anal. Calcd for C23H19N3O2S: C, 68.80; H, 4.77; 
N, 10.47. Found: C, 68.75; H, 4.74; N, 10.39. 
Compound T7: Yield = 82%, mp 278-280 ºC, Rf = 0.43, 
1H-
NMR (CDCl3) δ: 8.01(m, 4H; BZ), 7.89 (m, 4H; Ph), 6.96-
7.65 (m, 3H; Ph), 4.15 (d, J = 2.1 Hz, 1H; 2-CH), 2.37 (s, 
2H; 5-CH2), 1.80 (s, 3H; OCH3), 1.58 (s, 3H; OCH3). IR 
(KBr) cm
-1: 3180, 1682, 1227, 1115, 784, 747, 722, 639. EI-
MS  m/z: 431.42 (Calcd for: 431.50). Anal. Calcd for 
C24H21N3O3S: C, 66.80; H, 4.90; N, 9.74. Found: C, 66.76; 
H, 4.83; N, 9.72.  
Compound T8: Yield = 80%, mp 198-200 ºC, Rf = 0.48, 
1H-
NMR (CDCl3) δ: 8.02 (m, 4H; BZ), 7.63 (m, 4H; Ph), 6.90-
7.44 (m, 4H; Ph), 4.15 (d, J = 2.2 Hz, 1H; 2-CH), 2.49 (s, 
2H; 5-CH2), 2.05 (s, 3H; OCH3), 1.92 (s, 3H; OCH3), 3.05 (s, 
3H; O-CH3), 2.92 (s, 3H; O-CH3). IR (KBr) cm
-1: 3177, 
1682, 1229, 1115, 784, 720, 637. EI-MS m/z: 461.42(Calcd 
for C25H23N3O4S: 461.52). Anal. Calcd for: C, 65.06; H, 5.02; 
N, 9.17. Found: C, 64.97; H, 4.98; N, 9.14.  
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Scheme 1: Synthetic scheme of 2-[4-(azetidin-2-one)-3-Chloro-4- phenyl] 
1H-Phenyl benzimidazoles and 2-(thiazolidin-4-one) Phenyl]-1H-
Phenylbenzimidazoles 
PHARMACOLOGICAL EVALUATION 
Antimicrobial activity 
The antibacterial activity 
[15] of the synthesized compounds 
was tested against gram (+) bacteria (Bacillus cereus 
ATCC11778,  Micrococcus  luteus ATCC8341, 
Staphylococcus aureus ATCC9144  and  Salmonella 
epidermidis ATCC155) and gram (-) bacteria (Escherichia 
coli ATCC25922 and Klebssiela pneumoniae ATCC29665) 
using nutrient agar medium and fungi (Aspergillus niger 
ATCC9029 and Candida albicans ATCC2091) using 
sabourand dextrose agar medium.  
Paper disc diffusion method 
The sterilized (autoclaved at 120°C for 30 min), liquefied 
medium (40-50°C) was inoculated (1 ml/100 ml of medium) 
with the suspension of the microorganism (matched to 
McFarland barium sulphate standard) and poured into the 
petridish to give a depth of 3-4mm. The paper discs 
impregnated with the test compounds (50 μg/ml, dimethyl 
sulphoxide as solvent) were placed on the solidified medium. 
The plates were refrigerated (pre-incubated) for two hours at 
4°C and then incubated at 37°C for 24 h and 48 h for 
antibacterial and antifungal activity respectively at the end of 
which the zone of inhibition was given in Table 1. Cefaclor 
(30  μg/disc) and fluconazole (100 μg/disc) were used as 
standards.  
Minimum inhibitory concentration 
The minimum inhibitory concentration 
[16] (MIC) against the 
bacterial strains was determined by the test tube dilution 
technique using Mueller-Hinton nutrient broth. A series of 
glass tubes containing different concentrations of the 
synthesized compounds (in dimethyl sulphoxide) with the 
medium was inoculated with the required amount of 
inoculum to obtain a suspension of microorganism, which 
contains 10
5 CFU/ml. One growth control tube was prepared 
without the addition of microorganism. The tubes were 
incubated at 37°C for 24 h. The minimum inhibitory 
concentration (MIC - μg/ml) was considered to be the lowest 
concentration that exhibited the same turbidity as the blank 
tube. The data are presented in Table 1.     
Analgesic activity 
[17-19]  
The analgesic activity was determined by acetic acid induced 
writhing method-using wistar albino mice (n = 6) of either 
sex selected by random sampling technique (25-30 g) were 
used for the study. Diclofenac sodium at a dose level of 25 
mg/kg served as standard drug for comparison. The negative 
control received solvent only (1% CMC). The test 
compounds at 200 mg/kg (suspended in 1% CMC) were 
administered orally by intragastric tube 30 min prior to 
intraperitoneal administration of the writhing agent (0.6 % 
v/v aqueous acetic acid–1ml/100g). The percent analgesic 
activity (PAA) was calculated by the following formula, 
where T1 is the reaction time (s) before treatment, and T2 is 
the reaction time (s) after treatment. The writhings produced 
in the animal were observed for 20 minutes and the 
percentage protection was calculated by following formula 
for analgesic activity. The results are given in Table 2.  
% Protection = 100 – [(experimental/control) × 100] 
Anti-inflammatory activity 
[17-19]  
The anti-inflammatory activity was evaluated by 
Carrageenan induced rat paw edema method. Albino rats of 
wistar strain weighing 150-200 g of   either sex were divided 
into six animals in each group. 1 % CMC suspensions of the 
test compounds were administered intraperitoneally in a dose  Anbalagan et al. / Synthesis and Biological Activity of 2-(Thiazolidin-4-One) Phenyl]-………………. 
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Table 1:  Antibacterial and Antifungal activity of the Title compounds( A1-8 and T1-8) 
Antibacterial activity 
Zone of inhibition and Minimum Inhibitory Concentration (MIC) 
Antifungal activity 
Zone of inhibition (MIC)  Compounds 
BC SA ML SE  EC  KP  AN  CA 
A1.  22 (75)  15 (75)  22 (75)  24 (65)  22 (80)  20 (80)  12 (85)  24 (65) 
A2 25 (70)  17 (80)  22 (75)  25 (65)  24 (75)  26 (70)  08 (100)  20 (95) 
A3 24 (70)  18 (80)  21 (75)  27 (50)  26 (80)  24 (75)  10 (90)  20 (85) 
A4 22 (75)  15 (75)  20 (70)  23 (60)  18 (80)  21 (70)  14 (85)  24 (70) 
A5 20 (60)  13 (75)  18 (75)  22 (60)  16 (80)  14 (80)  13 (85)  12 (100) 
A6 24 (70)  15 (80)  19 (70)  20 (70)  15 (80)  15 (80)  15 (75)  22 (75) 
A7 23 (75)  17 (85)  20 (75)  24 (65)  20 (70)  10 (80)  14 (90)  18 (80) 
A8 24 (70)  16 (80)  21 (75)  26 (70)  19 (70)  16 (80)  16 (80)  17 (85) 
T1 15 (50)  15 (75)  22 (65)  25 (70)  23 (65)  18 (80)  13 (85)  19 (80) 
T2 20 (55)  17 (80)  20 (70)  18 (75)  25 (65)  20 (75)  12 (85)  24 (65) 
T3 19 (60)  16 (75)  21 (70)  22 (75)  26 (65)  19 (75)  10 (90)  20 (65) 
T4 17 (65)  15 (75)  22 (75)  20 (85)  22 (80)  16 (80)  13 (90)  22 (80) 
T5 15 (50)  13 (80)  22 (65)  16 (80)  25 (75)  15 (80)  08 (100)  24 (65) 
T6 16 (65)  12 (75)  18 (75)  18 (80)  20 (80)  14 (90)  12 (85)  24 (65) 
T7 18 (70)  14 (75)  19 (85)  16 (80)  20 (75)  15 (80)  10 (85)  20 (90) 
T8 19 (75)  11 (70)  20 (80)  20 (70)  18 (80)  14 (85)  11 (90)  20 (90) 
Cefaclor  27 25  23 34  29  27  -  - 
Fluconazole  - -  - -  -  -  18  23 
Zone of Inhibition in mm & MIC in μg/ml 
Significance levels: 
*p < 0.001 compared to control 
Bacillus cereus (BC), Staphylococcus aureus (SA), Micrococcus luteus (ML), Salmonella epidermidis (SE), Escherichia coli (EC), Klebssiela pneumoniae(KP), 
Aspergillus niger (AN) and Candida albicans (CA). 
 
Table 2: Analgesic activity and Anti-inflammatory activity of the Title compounds(1-16) 
Analgesic activity  Anti-inflammatory activity   
Compounds  Mean Writhings ± SEM  % Protection  Paw value Mean ± SEM  % Decrease in paw value 
A1.  17.33 ± 0.95*  54.99  0.28 ± 0.02*  65.0 
A2 22.83 ± 1.08  40.70  0.32 ± 0.03*  60.0 
A3 15.66 ± 0.8*  59.32  0.26 ± 0.02*  67.5 
A4 19.3 ± 0.97*  49.87  0.25 ± 0.03*  68.75 
A5 21.5 ± 1.9  44.16  0.28 ± 0.03*  65.0 
A6 23.3 ± 1.4  39.48  0.31 ± 0.03*  61.25 
A7 23.85 ± 1.5  38.05  0.27 ± 0.03*  66.25 
A8 24.6 ± 1.8  36.10  0.35 ± 0.05  56.25 
T1 10.3 ± 0.7*  73.25  0.22 ± 0.05*  72.5 
T2 14.33 ± 0.85*  62.78  0.26 ± 0.05*  67.5 
T3 8.2 ± 0.8*  78.70  0.21 ± 0.02*  73.75 
T4 12.66 ± 1.2*  67.12  0.28 ± 0.02*  65.0 
T5 13.85 ± 1.6*  64.03  0.30 ± 0.02*  62.5 
T6 10.66 ± 1.1*  72.31  0.28 ± 0.02*  65.0 
T7 9.5 ± 0.9*  75.32  0.30 ± 0.03*  62.5 
T8 8.8 ± 0.74*  77.14  0.28 ± 0.02*  65.0 
Control  38.5 ± 0.56  ------  0.80 ± 0.003  --- 
Diclofenac  7.5 ± 0.6*  80.52  0.30 ± 0.02*  62.50 
Significance levels: 
*p < 0.001 compared to control 
 
of 200 mg/kg. The control group was given only 1 % CMC 
suspensions. One group was administered with diclofenac 
sodium as standard drug, intraperitoneally in a dose of 25 
mg/kg.  After 30 min of the administration of test compounds 
paw edema was induced in albino rats injected carrageenen 
(0.1ml of 1.0 % solution in 0.9 % saline) into subplantar 
region of the left hind paw. After 4 h the increase in rat paw 
volume was recorded. The anti-inflammatory activity was 
measured in terms of percentage inhibition of edema of each 
group was calculated against control group. The given value 
is given in Table 2. 
% Reduction of edema = [(control-test)/control] × 100 
 
RESULTS AND DISCUSSION 
2-(4-aminophenyl)-benzimidazole 
[11] was treated with 
different substituted aromatic aldehydes to produce Schiff 
base. 
[12]  The Schiff bases were subjected to addition 
reactions with chloroacetyl chloride in the presence of 
triethylamine and mercaptoacetic acid in the presence of 1, 
4dioxane-anhydrous zinc chloride to produce 2-azetidinone 
derivatives
 and 4-thiazolidinone derivatives respectively. 
[13-
14] The chemical structures of the synthesized compounds 
were confirmed by means of IR,
 1H-NMR, mass spectral and 
elemental analysis. The synthesized compounds were 
screened for antibacterial (Bacillus cereus, Escherichia coli, 
Micrococcus luteus, Klebssiela pneumoniae, Staphylococcus 
aureus and Salmonella epidermidis), antifungal (Aspergillus 
niger and Candida albicans), analgesic activity by writhing 
reflex method and anti-inflammatory activity by carrageenen 
induced paw edema method. The synthesized compounds 
showed good antibacterial and antifungal activity against all 
tested organisms by disc diffusion method. The MIC of the 
compounds A 1-8 and T 1-8 for S. aureus (70-85 μg/ml), B. 
cereus (50-75 μg/ml), E. coli (65-80 μg/ml) M. luteus, (65-85 
μg/ml) K. pneumoniae, (70-90 μg/ml) and S. epidermidis(60-
85  μg/ml),  antifungal  A. niger (75-100  μg/ml) and C. 
albicans  (65-100  μg/ml)). All the synthesized compounds 
showed significant analgesic activity by writhing reflex 
method and anti-inflammatory activity by carrageenen 
induced paw edema method.  The thiazolidinone derivatives 
have good analgesic and anti-inflammatory activity in this 
prominent activity produced by 2-[2-(thiazolidin-4-one) 
Phenyl]-1H-Phenylbenzimidazole T1 and 2-[2-(thiazolidin-4-Anbalagan et al. / Synthesis and Biological Activity of 2-(Thiazolidin-4-One) Phenyl]-………………. 
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one) 4-hydroxyPhenyl]-1H-Phenylbenzimidazole T 3 at the 
dose of 200 mg/kg was found to equivalent to diclofenac (25 
mg/kg).  
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